Immuneering Corporation (IMRX) has a negative trailing P/E of -4.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 72.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -22.94%, forward earnings yield 1.38%.
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -30.8 | 0.00 | -36.41 | 123.80 | - |
| 2020 | -13.9 | -0.13 | -10.57 | 102.82 | - |
| 2021 | -12.7 | -15.99 | 2.73 | 204.62 | - |
| 2022 | -2.5 | -0.05 | 1.17 | 403.77 | - |
| 2023 | -3.9 | -7.30 | 2.31 | 0.00 | - |
| 2024 | -1.1 | -0.13 | 1.59 | 0.00 | - |
| 2025 | -5.2 | 0.14 | 1.33 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.32 | $1.92M | $-8.06M | -419.9% |
| 2020 | $-0.67 | $2.31M | $-17.04M | -737.2% |
| 2021 | $-1.27 | $2.08M | $-33.54M | -1612.3% |
| 2022 | $-1.87 | $316.95K | $-49.28M | -15548.7% |
| 2023 | $-1.88 | $0.00 | $-53.47M | - |
| 2024 | $-2.04 | $0.00 | $-61.04M | - |
| 2025 | $-1.27 | $0.00 | $-56.02M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.35 | $-2.05 – $-0.94 | $21.27M | $21.27M – $21.27M | 5 |
| 2027 | $-1.35 | $-1.54 – $-1.17 | $16M | $16M – $16M | 4 |
| 2028 | $-1.29 | $-2.28 – $0.33 | $51.75M | $51.75M – $51.75M | 4 |
| 2029 | $-0.64 | $-0.64 – $-0.64 | $109.06M | $109.06M – $109.06M | 2 |
| 2030 | $0.07 | $0.07 – $0.07 | $191.78M | $191.78M – $191.78M | 2 |
